{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mikhailova E"],"funding":["RFBR","Russian Foundation for Basic Research","Russian Science Foundation"],"pagination":["5445"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9658935"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(21)"],"pubmed_abstract":["We aimed to develop an antibody panel and data analysis algorithm for multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease (MRD) detection in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated with CD19-directed therapy. The development of the approach, which was adapted for the case of possible CD19 loss, was based on the additional B-lineage marker expression data obtained from a study of primary BCP-ALL patients, an analysis of the immunophenotypic changes that occur during blinatumomab or CAR-T therapy, and an analysis of very early CD19-negative normal BCPs. We have developed a single-tube 11-color panel for MFC-MRD detection. CD22- and iCD79a-based primary B-lineage gating (preferably consecutive) was recommended. Based o"],"journal":["Cancers"],"pubmed_title":["Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy."],"pmcid":["PMC9658935"],"funding_grant_id":["18-29-09132","17-29-06052","20-75-10091"],"pubmed_authors":["Zerkalenkova E","Popov A","Novichkova G","Illarionova O","Mamedov I","Miakova N","Maschan M","Shelikhova L","Karachunskiy A","Mikhailova E","Komkov A","Olshanskaya Y"],"additional_accession":[]},"is_claimable":false,"name":"Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy.","description":"We aimed to develop an antibody panel and data analysis algorithm for multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease (MRD) detection in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated with CD19-directed therapy. The development of the approach, which was adapted for the case of possible CD19 loss, was based on the additional B-lineage marker expression data obtained from a study of primary BCP-ALL patients, an analysis of the immunophenotypic changes that occur during blinatumomab or CAR-T therapy, and an analysis of very early CD19-negative normal BCPs. We have developed a single-tube 11-color panel for MFC-MRD detection. CD22- and iCD79a-based primary B-lineage gating (preferably consecutive) was recommended. Based o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T00:36:54.672Z","creation":"2025-04-04T00:36:54.672Z"},"accession":"S-EPMC9658935","cross_references":{"pubmed":["36358863"],"doi":["10.3390/cancers14215445"]}}